HHS Public Access Author manuscript IJC Metab Endocr. Author manuscript; available in PMC 2017 October 20.

Similar documents
NIH Public Access Author Manuscript Int J Cardiol. Author manuscript; available in PMC 2014 November 20.

Coagulation an Overview Dr.Abdolreza Abdolr Afrasiabi Thal assem a & Heamophili hilia G ene i tic R esearc C en er Shiraz Medical Medic University

VENOUS THROMBOEMBOLISM AND CORONARY ARTERY DISEASE: IS THERE A LINK?

HHS Public Access Author manuscript J Psychosom Res. Author manuscript; available in PMC 2017 July 01.

Primary Exam Physiology lecture 5. Haemostasis

Clinical Investigation and Reports

John Davidson Consultant in Intensive Care Medicine Freeman Hospital, Newcastle upon Tyne

WHITE PAPERS PRESENTATION VIDEO DOCUMENTATION EXPERIMENT WO NDCLOT. The WoundClot Principals for Effective Bleeding Control PRESENTATION

"DENTAL MANAGEMENT OF A PATIENT TAKING ANTICOAGULANTS"

Effective Date: Approved by: Laboratory Director, Jerry Barker (electronic signature)

HHS Public Access Author manuscript Emerg Med J. Author manuscript; available in PMC 2017 September 01.

Coagulation, Haemostasis and interpretation of Coagulation tests

General approach to the investigation of haemostasis. Jan Gert Nel Dept. of Haematology University of Pretoria 2013

NIH Public Access Author Manuscript JAMA Intern Med. Author manuscript; available in PMC 2014 June 24.

Prothrombin Complex Concentrate- Octaplex. Octaplex

Insights on the Quality of Coagulation Testing

ACQUIRED COAGULATION ABNORMALITIES

L iter diagnostico di laboratorio nelle coagulopatie congenite emorragiche

Topics of today lectures: Hemostasis

Hemostasis. Learning objectives Dr. Mária Dux. Components: blood vessel wall thrombocytes (platelets) plasma proteins

Introduction to coagulation and laboratory tests

Platelet-fibrin clot. 50Kd STEMI. Abciximab. Video of a IIb/IIIa inhibitor in action. Unstable Angina and non-stsegment

Diagnosis of hypercoagulability is by. Molecular markers

Internal Quality Control in the Haemostasis laboratory. Dr Steve Kitchen Sheffield Haemophilia and Thrombosis centre & UK NEQAS Blood Coagulation

THROMBOTIC DISORDERS: The Final Frontier

Cangrelor: Is it the new CHAMPION for PCI? Robert Barcelona, PharmD, BCPS Clinical Pharmacy Specialist, Cardiac Intensive Care Unit November 13, 2015

Post-Traumatic Stress Disorder (PTSD) Symptoms Predict Delay to Hospital in Patients with Acute Coronary Syndrome

Chapter 19. Hemostasis

This slide belongs to iron lecture and it is to clarify the iron cycle in the body and the effect of hypoxia on erythropoitein secretion

HEME 10 Bleeding Disorders

Using DOACs in CAD Patients in Sinus Ryhthm Results of the ATLAS ACS 2, COMPASS and COMMANDER-HF Trials

Chapter 1 Introduction

Timing of Anti-Platelet Therapy for ACS (EARLY-ACS & ACUITY) Mitchell W. Krucoff, MD, FACC

Cardiac patients perceptions of neighboring patients risk: influence on psychological stress in the ED and subsequent posttraumatic stress

Perioperative Infarcts: Epidemiology, predictors and post-op monitoring

Handbook for Venous Thromboembolism

CABG in the Post-Aprotinin Era: Are We Doing Better? Ziv Beckerman, David Kadosh, Zvi Peled, Keren Bitton-Worms, Oved Cohen and Gil Bolotin

Blood coagulation and fibrinolysis. Blood clotting (HAP unit 5 th )

KCS Congress: Impact through collaboration

FastTest. You ve read the book now test yourself

The effect of supplementation with vitamin D on recurrent ischemic events and sudden cardiac death in patients with acute coronary syndrome

What are blood clots?

Debate: New Generation Anti-Coagulation Agents are a Better Choice than Warfarin in the Management of AF

Unstable angina and NSTEMI

Anticoagulants. Pathological formation of a haemostatic plug Arterial associated with atherosclerosis Venous blood stasis e.g. DVT

A Look at Patient Compliance to INR Testing and Therapeutic Range Management of Patients on Warfarin at Agassiz Medical Center.

Durlaza. Durlaza (aspirin) Description

Hematologic Disorders. Assistant professor of anesthesia

Supplemental Information

HEMOSTASIS Quality Time saving Economy Practicability Quality assurance Precision

Transfusion Requirements and Management in Trauma RACHEL JACK

TRANSFUSION GUIDELINES FOR CARDIOTHORACIC UNIT 2006

FACTOR Xa AND PAR-1 BLOCKER : ATLAS-2, APPRAISE-2 & TRACER TRIALS

Depression in Peripheral Artery Disease: An important Predictor of Outcome. Goals. Goals. Marlene Grenon, MD Assistant Professor of Surgery, UCSF

Treatment of the Medically Compromised Patient

Surgical Outcomes: A synopsis & commentary on the Cardiac Care Quality Indicators Report. May 2018

Which drug do you prefer for stable CAD? - P2Y12 inhibitor

Xi Li, Jing Li, Frederick A Masoudi, John A Spertus, Zhenqiu Lin, Harlan M Krumholz, Lixin Jiang for the China PEACE Collaborative Group

Study population The study population comprised adult patients receiving UFH therapy for a broad range of conditions.

When the learner has completed this module, she/he will be able to:

Asian AMI Registry Session The 17 th Joint Meeting of Coronary Revascularization (JCR 2017) Busan, Korea Dec 8 th 2017

Dr. MUBARAK ABDELRAHMAN MD PEDIATRICS AND CHILD HEALTH Assistant Professor FACULTY OF MEDICINE -JAZAN

Chest Pain. Dr Robert Huggett Consultant Cardiologist

Interpersonal Conflict & Role Transitions Predict Poor Adherence to Aspirin after Acute Coronary Syndromes

Dr Shikha Chattree Haematology Consultant Sunderland Royal infirmary

Blood Thinner Agent. Done by: Meznah Al-mutairi Pharm.D Candidate PNU Collage of Pharmacy

Statin pretreatment and presentation patterns in patients with acute coronary syndromes

Step 2. Common Blood Tests, and the Coulter Counter Readout

Supplementary Online Content

Acute coronary syndromes

Optimal antiplatelet and anticoagulant therapy for patients treated in STEMI network

Mohammadreza Tabatabaei IBTO COAG LAB

Anticoagulants and Head Injuries. Asaad Shujaa,MD,FRCPC,FAAEM Assistant Professor,weill Corneal Medicne Senior Consultant,HMC Qatar

Recombinant Activated Factor VII: Useful. Department of Surgery Grand Rounds 11/8/10 David Mauchley MD

Recent studies have found that elevated levels of coagulation

Outline Anti-coagulant and anti-thrombotic drugs Haemostasis and Thrombosis Year 3 Dentistry

Anatomy and Physiology

Developed for Scotland by the National Plasma Product Expert Advisory Group (NPPEAG)

APPENDIX F: CASE REPORT FORM

Hemostasis. Clo)ng factors and Coagula4on NORMAL COAGULATION. Overview of blood coagula4on. The Cascade Theory 5/1/12. Clot

Disseminated Intravascular Coagulation. M.Bahmanpour MD Assistant professor IUMS

Hemostasis and. Blood Coagulation

Objectives. Acute Coronary Syndromes; The Nuts and Bolts. Overview. Quick quiz.. How dose the plaque start?

Ch. 45 Blood Plasma proteins, Coagulation and Fibrinolysis Student Learning Outcomes: Describe basic components of plasma

Perioperative Management After Coronary Stenting: Risk Assessment Before Surgery. Christian Seiler No conflict of interest to declare.

CLINICIAN INTERVIEW RECOGNIZING ACS AND STRATIFYING RISK IN PRIMARY CARE. An interview with A. Michael Lincoff, MD, and Eric R. Bates, MD, FACC, FAHA

M B Garvey. University of Toronto

Mabel Labrada, MD Miami VA Medical Center

Haemostasis & Coagulation disorders Objectives:

Transfer in D2B. Scott D Friedman, MD FACC Medical Director, Cardiology Services Shore Health System of Maryland. The Problem

Using the PTSD Checklist for DSM-5 (PCL-5)

VTE in Children: Practical Issues

Thrombosis. Jeffrey Jhang, M.D.

Impact of in-hospital delay to invasive treatment of NSTEMI patients on early and 12-month clinical outcomes

GUIDELINE: ASSESSMENT OF BRUISING & BLEEDING IN CHILDREN. All children in whom there is concern regarding bruising / bleeding

Vehicle ACT. 180 min. Time After Current Initiation (min) 180 min. Vehicle. UFH (75 U/kg) Anti-Factor Xa. Time After Current Initiation (min)

Safety of Arthrocentesis and Joint Injection in Patients Receiving Anticoagulation at Therapeutic Levels

UNIT VI. Chapter 37: Platelets Hemostasis and Blood Coagulation Presented by Dr. Diksha Yadav. Copyright 2011 by Saunders, an imprint of Elsevier Inc.

Coagulation Disorders. Dr. Muhammad Shamim Assistant Professor, BMU

When should I transfuse platelets and plasma for children? Dr Liz Chalmers. Consultant Paediatric Haematologist Royal Hospital for Children Glasgow

Transcription:

HHS Public Access Author manuscript Published in final edited form as: IJC Metab Endocr. 2016 June ; 11: 1 2. doi:10.1016/j.ijcme.2016.03.002. Posttraumatic stress disorder symptoms and hypercoagulability during emergency department evaluation for acute coronary syndrome Vy Thuy Ho, Columbia University College of Physicians and Surgeons, New York, NY, Daichi Shimbo, Joan Duer-Hefele, William Whang, Melinda Chang, and Donald Edmondson * Posttraumatic stress disorder is associated with risk for incident and recurrent cardiovascular disease (CVD) and mortality, but the mechanisms for the association are unclear [4]. Recent studies have shown that PTSD is associated with greater coronary artery calcium [1], reduced coronary blood flow [8], and autonomic imbalance [8]. Thrombus formation is critical in the pathogenesis of coronary artery disease, and faster clotting speed as measured by activated partial thromboplastin time (aptt) has been associated with recurrent cardiovascular events in acute coronary syndrome (ACS) patients [2]. Only two small studies have investigated the association of PTSD with markers of coagulation. One case control study (N = 14 PTSD) suggested a linear association of PTSD symptoms with clotting factors VII, VIII, XII, fibrinogen, and D-dimer [9]. Another study This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). * Corresponding author at: Center for Behavioral Cardiovascular Health, Columbia University Medical Center, 622 West 168 Street, PH9-317, New York, NY 10032,. Conflict of interests The authors have no competing interests to report.

Ho et al. Page 2 found increased levels of vwf antigen and factor VIII in 30 patients with severe chronic PTSD [6]. In order to determine whether PTSD symptoms are associated with hypercoagulability, a mechanism underlying ACS onset, we tested the association of PTSD symptoms from a prior traumatic event with clotting parameters in 99 patients who presented with an ACS event. The Reactions to Acute Care in Hospitalization (REACH) study is an ongoing observational cohort study of psychosocial factors and cardiac/mortality risk in cardiac patients being evaluated for ACS. Participants, who later had ACS diagnosis confirmed, underwent testing for aptt, prothrombin time (PT), and platelet count as part of a cardiac evaluation in the ED. Either during inpatient stay or by telephone a median of 3 days later, participants completed the Life Events Checklist [5] for prior traumatic event burden and the PTSD Checklist-Civilian version (PCL) with reference to the most stressful prior traumatic event. The PCL provides a continuous measure of PTSD symptom severity over 17 items with high diagnostic utility a cutoff score of 50 is 82% sensitive, 83% specific for PTSD diagnosis via Structured Clinical Interview for DSM disorders [10]. Age, sex, ACS type [Non-ST elevation myocardial infarction (NSTEMI) or unstable angina (UA)], daily aspirin or anticoagulant history, ED aspirin, heparin, or warfarin receipt, Global Registry of Acute Coronary Events (GRACE) score, and Charlson comorbidity index were taken from chart review. Covariates were chosen a priori for variates known to influence aptt. All participants provided informed consent, and the research was carried out in accordance with the Declaration of Helsinki. Three linear regression models were tested to determine whether PCL-C scores (log transformed) were associated with hypercoagulability (aptt and PT) and platelet count with adjustment for the covariates above. We tested for collinearity using the variance inflation factor, no significant collinearity was found. In 99 participants (Table 1), the cumulative traumatic event burden was 3.3 ± 2.9 events, with a mean PCL score of 27 ± 12 (22% screened positive for pre-existing PTSD at a cutoff of 35). The most common trauma inducing event was the sudden, unexpected death of a close loved one (37%). aptt and PT in the sample were 30.4 ± 8.3 and 14.4 ± 3.0 s, respectively. In the fully adjusted model, higher PTSD symptoms were associated with lower aptt values (β = 0.22, p =.03); which corresponds to 1.5 s of aptt per 10 points on the PCL. No other variable was statistically significant, but history of anticoagulant use (β = 0.17, p =.09), GRACE score (β = 0.26, p =.09) and heparin receipt in the ED (β = 0.19, p =.06) were marginally associated with greater aptt. The full model explained 13% of the variability in aptt [F(11,87) = 2.30, p =.02; R 2 adj =.13]. PTSD symptoms were not significantly associated with PT values (β = 0.06, p =.41) or platelet count (β = 0.01, p =.98). (See Table 2.) We examined whether PTSD symptoms were associated with hypercoagulability in a cohort of ACS patients during ED evaluation. Although PTSD can occur due to an ACS event, we screened for PTSD symptoms in relation to a traumatic event prior to arriving to the ED. We

Ho et al. Page 3 found that PTSD symptoms may be associated with reduced aptt, but not PT or platelet count. The aptt reflects the activity of the intrinsic and common coagulation pathways, including Factor VIII, IX, X, XI, and XII. Conversely, PT assesses the activity of the extrinsic pathway, particularly Factor VII, a Vitamin K-dependent procoagulant with a short half-life [7]. Therefore, our study suggests that PTSD symptoms may be associated with activation of the intrinsic and common coagulation pathways. Previously, Von Kanel et al. found that increased levels of fibrinogen and Factor VIII in patients with PTSD, suggesting subthreshold changes in coagulation [9]. Our findings suggest a detectable change in aptt during an acutely stressful experience, such as undergoing evaluation for a cardiac event in the ED. As such, patients with PTSD may exhibit a baseline level of subthreshold hypercoagulability, which becomes significant in the setting of subsequent acute stress. Arbab-Zadeh et al. proposed a perfect storm model for understanding the pathophysiology of acute coronary syndrome, wherein a multitude of biological events coalesce to precipitate ACS [3]. When applied to the relationship between PTSD and CVD, the perfect storm model captures the complexity of the physiological, psychiatric, and psychosocial factors that play a role in conferring disease. Our analysis suggests that hypercoagulability may be part of the constellation of processes that predispose PTSD patients to ACS onset. A limitation of this observational cohort study is that aptt represents the collective behavior of multiple coagulation factors, so the relative influence of individual coagulant proteins in fostering hypercoagulability cannot be determined. However, our findings provide preliminary evidence that the cardiovascular effects of PTSD may be partially explained by hypercoagulability. Additional research using more detailed analysis of clotting factors in large populations can further our understanding of the link between PTSD and cardiovascular risk. Further, serial testing of coagulation parameters may better characterize the extent and magnitude of hypercoagulability in PTSD patients over time. Acknowledgments This work was supported by grants R01 HL117832, R01 HL128310 and R01 HL123368 from the National Heart, Lung, and Blood Institute. References 1. Ahmadi N, Hajsadeghi F, Mirshkarlo HB, Budoff M, Yehuda R, Ebrahimi R. Post-traumatic stress disorder, coronary atherosclerosis, and mortality. Am J Cardiol. 2011; 108:29 33. [PubMed: 21530936] 2. Anand SS, Yusuf S, Pogue J, Ginsberg JS, Hirsh J. Investigators obototasfis, Relationship of activated partial thromboplastin time to coronary events and bleeding in patients with acute coronary syndromes who receive heparin. Circulation. 2003; 107:2884 2888. [PubMed: 12796128] 3. Arbab-Zadeh A, Nakano M, Virmani R, Fuster V. Acute coronary events. Circulation. 2012; 125:1147 1156. [PubMed: 22392862] 4. Edmondson D, Cohen BE. Posttraumatic stress disorder and cardiovascular disease. Prog Cardiovasc Dis. 2013; 55:548 556. [PubMed: 23621964] 5. Gray M, Litz B, Hsu J, Lombardo T. Psychometric properties of the life events checklist. Assessment. 2004; 11:330. [PubMed: 15486169]

Ho et al. Page 4 6. Robicsek O, Makhoul B, Klein E, Brenner B, Sarig G. Hypercoagulation in chronic post-traumatic stress disorder. IMAJ-Isr Med Assoc J. 2011; 13:548. 7. Suchman AL, Griner PF. Diagnostic decision: diagnostic uses of the activated partial thromboplastin time and prothrombin time. Ann Intern Med. 1986; 104:810 816. [PubMed: 3706933] 8. Vaccarino V, Goldberg J, Rooks C, Shah AJ, Veledar E, Faber TL, et al. Post-traumatic stress disorder and incidence of coronary heart disease: a twin study. J Am Coll Cardiol. 2013; 62:970 978. [PubMed: 23810885] 9. Von Känel R, Hepp U, Buddeberg C, Keel M, Mica L, Aschbacher K, et al. Altered blood coagulation in patients with posttraumatic stress disorder. Psychosom Med. 2006; 68:598 604. [PubMed: 16868270] 10. Weathers F, Litz B, Herman D, Huska J, Keane T. The PTSD Checklist (PCL): Reliability, Validity, and Diagnostic Utility. 1993

Ho et al. Page 5 Participant characteristics. Table 1 Age 61 ± 12 Male sex 65% Non-ST elevation MI 38% History of daily aspirin use 63% History of anticoagulant use a 7% Aspirin in ED prior to aptt 47% Heparin in ED prior to aptt 3% GRACE score b 91 ± 28 Charlson comorbidity indexc 1.9 ± 1.9 Lifetime traumatic events 3.3 ± 2.9 PCL-C scored 27 ± 12 aptte 30.4 ± 8.3 PT 14.4 ± 3.0 Platelet count 228 ± 60 Mean ± SD or % of sample a Warfarin or heparin use within 7 days prior to presentation. b Global Registry of Acute Coronary Events score. Higher scores represent greater 6-month risk (e.g., 100 127 predicts a 4.5 11% 6-month mortality risk). c Number of comorbidities weighted by associated mortality risk (<2 predicts <10% risk of 10-year mortality). d PTSD Checklist-Civilian. e Activated partial thromboplastin time.

Ho et al. Page 6 Table 2 Multiple regression predicting activated partial thromboplastin time (aptt) from PTSD symptom score, and demographic and clinical covariates. Variable B SE (B) β p Age.01.10.02.91 Sex.32 1.69.02.85 NSTEMI 2.53 1.68.15.14 GRACE cardiac risk score.08.05.26.09 Charlson Comorbidity score.48.49.11.33 Cumulative traumatic events.30.29.11.29 PCL-C PTSD symptoms (log transformed) 4.82 2.23.22.03 Daily aspirin history 2.07 1.77.12.25 Anticoagulant history 5.39 3.16.17.09 Aspirin in ED 1.37 1.60.08.39 Heparin in ED 8.97 4.68.19.06